Eli Lilly Gets FDA Approval for Ulcerative Colitis Treatment

By Ben Glickman

Eli Lilly said the U.S. Food and Drug Administration had approved Omvoh, its treatment for moderately to severely active ulcerative colitis in adults.
The pharmaceutical giant expects the treatment to be available in the U.S. in the coming weeks.

Lilly said the infusion treatment was the first interleukin-23p19 antagonist to be approved for the treatment of UC. The company said the compound plays a role in inflammation from UC.
The approval by the FDA was based on two Phase 3 trials of the treatment.
The company has already received approval for Omvoh in Japan and the European Union.
Write to Ben Glickman at [email protected]